Ibrutinib in previously treated Waldenström's macroglobulinemia Academic Article uri icon

Overview

MeSH Major

  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Pyrazoles
  • Pyrimidines
  • Waldenstrom Macroglobulinemia

abstract

  • Ibrutinib was highly active, associated with durable responses, and safe in pretreated patients with Waldenström's macroglobulinemia. MYD88 and CXCR4 mutation status affected responses to this drug. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01614821.).

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1501548

PubMed ID

  • 25853747

Additional Document Info

start page

  • 1430

end page

  • 40

volume

  • 372

number

  • 15